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Abstract
African American (AA) women have a lower overall incidence of breast cancer than do Caucasian
(CAU) women, but a higher overall mortality. Little is known as to why the incidence of breast
cancer is lower yet mortality is higher in AA women. Many studies speculate that this is only a
socio-economical problem. This investigation suggests the possibility that molecular mechanisms
contribute to the increased mortality of AA women with breast cancer. This study investigates the
expression of 14 genes which have been shown to play a role in cancer metastasis. Cell lines
derived from AA and CAU patients were analyzed to demonstrate alterations in the transcription
of genes known to be involved in cancer and the metastatic process. Total RNA was isolated from
cell lines and analyzed by RT-PCR analysis. Differential expression of the 14 targeted genes
between a spectrum model (6 breast cancer cell lines and 2 non-cancer breast cell lines) and a
metastasis model (12 metastatic breast cancer cell lines) were demonstrated. Additionally, an in
vitro comparison of the expression established differences in 5 of the 14 biomarker genes between
African American and Caucasian breast cell lines. Results from this study indicates that altered
expression of the genes Atp1b1, CARD 10, KLF4, Spint2, and Acly may play a role in the aggressive
phenotype seen in breast cancer in African American women.
Background
Cancer is characterized by excessive growth and spread of
abnormal cells. It affects all populations in the United
States and ranks second only to heart disease as the lead-
ing cause of death [1]. More than half the recognized types
of cancer share the property of metastatic activity [2]. It is
estimated that 1,399,790 new cases of cancer will be diag-
nosed in 2006. More than 564,830 Americans are
expected to die of cancer, equaling more than 1,500 peo-
ple each day. African American (AA) women exhibit a dis-
proportionate burden of cancer. The American Cancer
Society reported that in 2005 more than 63,000 AA were
expected to die from cancer [3]. For all cancers, cancer
death rates among AA are higher than other racial or eth-
nic populations in the United States [4]. In 2005, it was
estimated that 137,910 new cases of cancers would be
diagnosed among AA women. Among AA women, the
most common cancers will be breast, colon and rectum,
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and lung. Cancers among AA women are more frequently
diagnosed after the cancer has metastasized and spread to
regional or distant sites [3]. In 2006 more than 212,920
new cases of invasive breast cancer will be diagnosed and
41,430 women are expected to die due to the disease [1].
Although the 5-year survival rate among AA women diag-
nosed with breast cancer has improved, they still have a
decreased likelihood of surviving 5 years after diagnosis
than Caucasian (CAU) for all cancer sites and at all stages
of diagnosis. Much of this difference is believed to be due
to factors associated with poverty [5], which include
reduced access to medical care [6], diagnoses at a later
stage, when the disease has spread to regional or distant
tissues [7], and disparities in treatment [8,9]. The goal of
this study is to identify biological factors that may lead to
or increase the high mortality rate observed in AA.
Metastasis is the main cause of morbidity and mortality in
cancer patients. The selective distribution of metastases is
dictated by numerous factors, including complementary
adhesive contacts, the pattern of vascular flow from the
primary site, and molecular interactions between the
tumor cell and the stroma at the secondary site [10]. Our
lab has previously shown that of the 26 human matrix
metalloproteinases (MMPs), 12 have been shown to have
elevated expression in AA breast cancer cell lines when
compared to their CAU counterparts. Our results sug-
gested that there is altered expression of 12 MMPs in cell
lines derived from AA and CAU women. The data demon-
strated elevated expression of MMPs 3, 7, 8, 9, 11–15,
23B, 26, and 28 in AA women [11]. This investigation
indicated that altered expression of MMPs may play a role
in the aggressive phenotype seen in AA women. As a result
of the aforementioned study, an expanded gene list of
possible biomarkers that may be responsible for the
aggressive breast cancer observed in the AA women were
examined. The experiments were modeled using 14 of the
43 genes described in the study by Eckhardt et al. [12] to
create primers using the human analog gene sequences.
This study investigates the expression levels of 14 genes,
which have been shown to play a role in cancer and the
metastatic process, using breast cell lines derived from AA
and CAU women.
Methods
Cell Culture
Cell lines were purchased from American Type Culture
Collection (Rockville, MD, USA) and Coriell Cell Reposi-
tories (Camden, NJ). Cells were propagated in the recom-
mended media and given new media every 2 to 3 days
until 90% confluent. The spectrum model (Table 1) con-
tains 6 breast cancer cell lines and 2 non-cancer breast cell
lines. Of the 6 cell lines, three are derived from AA and
three derived from CAU. This model also contains two cell
lines from primary sites and one metastatic cell line. The
metastatic model (Table 2) consists of 12 metastatic
breast cancer cell lines from 6 AA and 6 CAU women.
RNA Extractions
RNA was extracted from the cell lines using RNAqueous
(Ambion, Austin, TX). Cells were collected by low speed
centrifugation and lysed by adding 200 μl of Lysis/Bind-
ing Solution. An equal volume of 64% ethanol was added
to the lysate. The lysate/ethanol mixture was transferred to
the RNAqueous Filter Cartridge and centrifuged for 1
minute at 13,400 rpm. The flow through was discarded
and 700 μl of Wash Solution 1 was added to the RNAque-
ous Filter Cartridge and centrifuged for 1 minute. The col-
umn was washed twice with 500 μl of Wash Solution 2/3
and eluted with 110 μl Elution Solution. Isolated RNA
was quantitated using the NanoDrop Spectrophotometer
(Wilmington, DE). All RNA samples were stored at -70°C
in RNA elution solution (Ambion, Austin, TX).
Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR)
The RT-PCR reactions were performed in a P/E GeneAmp
9700 thermocycler (Perkin-Elmer Co., Norwalk CT),
Table 1: Spectrum Model Cell Lines
CAUCASIAN (CAU)
MCF-12A Mammary gland; breast; epithelial; non-tumorigenic
HS578T Mammary gland; breast; carcinoma
MCF-7 Mammary gland; breast; epithelial; metastatic site: pleural effusion adenocarcinoma
CRL-2336 Mammary gland epithelial, primary ductal carcinoma
AFRICAN AMERICAN (AA)
AG11132 Mammary gland; breast; epithelial; non-tumorigenic
CRL-2315 Breast, primary ductal carcinoma
CRL-2329 Carcinoma, ductal, primary; breast; mammary gland
CRL-2320 Carcinoma, ductal, breast; mammary gland; from metastatic site: lymph nodeJournal of Carcinogenesis 2007, 6:8 http://www.carcinogenesis.com/content/6/1/8
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using the Access RT-PCR system (Promega, Madison, WI).
The reaction mixes were prepared by combining 27.5 μl of
nuclease free water, 10 μl of AMV, 1 μl Tfl 5X reaction
buffer, 2 μl dNTP mix, 50 pM of upstream primer, 50 pM
of downstream primer in 1.5 μl volume each, 3 μl 25 mM
MgSO4, 1.0 μl AMV reverse transcriptase, Tfl DNA
polymerase and 1 μg of total RNA in a 0.5 ml thin walled
Eppendorf tube on ice. The reaction mixes were then vor-
texed for 5 seconds and centrifuged. The PCR cycling pro-
file was as follows: 48°C for 1 minute for reverse
transcription of the RNA into cDNA, 94°C for 4 minutes
to deactivate the reverse transcriptase, and 30 cycling
sequences of denaturing at 94°C for 45 seconds, anneal-
ing at 55°C-58°C (Table 3) for 30 seconds, and extension
at 72°C for 1 minute with a final extension at 72°C for 10
minutes. An aliquot of 20 μl of each RT-PCR reaction was
run on 1.2% agarose gels, stained with ethidium bromide,
photographed and subjected to densitometic measure-
ments using the Chemi-Imager Tm 4000 (Alpha Innotech,
Corporation, San Leandro, CA). The primers used in this
study are listed in Table 3.
Results
RT-PCR Analysis
In order to ascertain the cells metabolic activity and equal
loading of 1 μg of RNA, expression levels of 18S and
GAPDH were analyzed. The mRNA expression levels of
18S were similar between AA and CAU cell lines (Figure
1). Differential expression of the mRNA levels GAPDH
was observed between AA and CAU cell lines (Figure 2) as
is often seen when utilizing this internal marker. The com-
parison of the individual relative densities of cancer cells
in both cell line models between AA and CAU women
revealed altered expression in 5 of the 14 potential
biomarkers (Atp1b1, CARD 10, KLF4, Spint2, and Acly)
(Tables 4 and 5). Elevated expression of Atp1b1, Spint2,
and Acly in AA women breast cancer cells were observed
when the expression levels of all AA and CAU women cell
lines were compared (Figures 3, 4, and 5). Lowered
expression of KLF4 and CARD 10 were observed when the
expression levels of all AA and CAU women cancer cell
lines were compared (Figures 6 and 7). Altered expression
of Atp1b1, CARD 10, KLF4, Spint2, and Acly in AA breast
cancer cells was observed when the overall averages of the
expression levels of all AA and CAU cancer cell lines were
compared (Figure 8).
Discussion
Breast cancer is described as heterogeneous because it is a
different disease in different women, a different disease in
different age groups and has different cell populations
within the tumor itself. It is the most frequently diagnosed
cancer in women. The main types of breast cancer are duc-
tal carcinoma in situ, invasive ductal carcinoma, lobular
carcinoma in situ, invasive lobular carcinoma, medullary
carcinoma, and Paget's disease of the nipple. Carcinomas
are malignant tumors that begin in the lining layers of
organs [13].
There are many factors that contribute to breast cancer
development. The risk of being diagnosed increases as
individuals' age. The primary factors that increase the risk
are an inherited mutation of the BRCA1 and/or BRCA 2
genes, a family history of breast cancer, high breast den-
sity, and a confirmed biopsy of hyperplasia. Although the
BRCA mutations are one of the primary factors for devel-
Table 2: Metastatic Model Cell Lines
CAUCASIAN (CAU)
MCF-12A Mammary gland; breast; epithelial; non-tumorigenic
CAMA-1 Mammary gland; metastatic site: pleural effusion adenocarcinoma
CRL-2351 Mammary gland; metastatic site: malignant pleural effusion adenocarcinoma
HTB-30 Mammary gland; metastatic site: pleural effusion adenocarcinoma
CRL-2327 Mammary gland; metastatic site: adenocarcinoma and pleural effusion cells adenocarcinoma
MCF-7 Mammary gland; breast; epithelial; metastatic site: pleural effusion adenocarcinoma
HTB-27 Mammary gland; metastatic site: brain adenocarcinoma
AFRICAN AMERICAN (AA)
AG11132 Mammary gland; breast; epithelial; non-tumorigenic
CRL-7721 Mammary gland; metastatic site: pleural effusion carcinoma
CRL-1504 Mammary gland; metastatic site: ascites ductal carcinoma
CRL-2330 Mammary gland: primary metaplastic carcinoma lymph node metastasis
CRL-2320 Carcinoma, ductal, breast; mammary gland; from metastatic site: lymph node
HTB-24 Mammary gland; metastatic site: pleural effusion ductal carcinoma
HTB-132 Mammary gland: metastatic adenocarcinoma of the breast
CRL-2335 Mammary gland: metastatic adenocarcinoma of the breastJournal of Carcinogenesis 2007, 6:8 http://www.carcinogenesis.com/content/6/1/8
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oping breast cancer, it accounts for only 5% of all breast
cancer cases. Women that carry these mutations, however,
have a lifetime risk of developing breast cancer ranging
from 35% to 85%. There are other factors that have been
linked to increased risk of breast cancer. These include a
long menstrual history, obesity after menopause, recent
use of oral contraceptives, having more than one alco-
holic drink per day, and postmenopausal hormone ther-
apy. This is especially true of the use of combined estrogen
and progestin therapy [14].
This study demonstrates the validity of using the spectrum
and metastasis model systems to identify expression pro-
files that may be unique to metastatic breast cancer in AA
women. We expanded our potential biomarker gene list to
include 14 genes that have been shown to play roles in
cancer. We observed altered expression of 5 genes in AA
cell lines when compared to their CAU counterparts. This
evidence suggests that the altered expression levels of
CARD10, KLF4, Acly, Atp1b1, and Spint2 may be contrib-
uting factors in the higher mortality rates of AA breast can-
cer patients. The candidates identified could not only be
useful in early detection of metastatic potential in AA
women, but also provide support for the concept that
there are clearly genetic factors that play a role in the
aggressive phenotype seen in this population.
The data show that the mRNA transcript encoding Na K-
ATPase (Atp1b1) was elevated in the cancer cell lines com-
pared to the normal cell lines and exhibited altered
expression profiles between AA and CAU cell lines. The
active form of Atp1b1 is composed of a 100–112 kDa cat-
alytic ct-subunit and a 45–60 kDa glycoprotein 13-subu-
nit [15]. Three different isoforms of α (α1, α2 and α3) and
β (β1, β2 and β3) subunits are known [16-18]. At the aa
level, α isoforms share 85% sequence similarity [16] while
50% similarity is found among β isoforms [18]. Interest-
ingly, the expression of different isoforms seems to follow
a tissue-specific pattern. The α1 and β1 isoforms are pro-
duced in most tissues, whereas α2, α3 and β2 are produced
predominantly in the brain [17,19]. The abundance of
ATP1B1 has recently been found to be a useful tool for the
proper reclassification of samples as either tumors of low
malignant potential or the invasive tumors of epithelial
ovarian cancers [20].
We observed decreased levels of both Caspase recruitment
domain family (CARD) and Kruppel-like-factor 4 (KLF4)
expression in both primary and metastatic cell lines com-
pared with the normal cell lines, with the lowest expres-
sion levels occurring in the metastatic cell lines. CARDs
are protein modules found in many proteins that regulate
apoptosis [21-23]. A total of 21 human CARD-containing
proteins have been identified. Members of this family
include caspases 1, 2, 4, 5, 9, and 13, Apaf-1, CARD4
(Nod1), Nod2, CARD7 (DEFCAP/NAC), c-IAP-1, c-IAP-2,
RICK (RIP2/CARDIAK), ARC, BCL10, RAIDD, ASC, Ice-
berg, CARD9, CARD11, and CARD14. CARD10 is a novel
Table 3: Gene List
Gene Accession Number Symbol Primer Sequence Annealing Temperature °C Base pair size (bp)
ATP citrate lyase AW538652 Acly CATCCACAGGCTAACACC
CATCCTAACGCCCTACAA
58 179
ATPase, Na+/K+ transporting, b1 polypeptide AW544616 Atp1b1 CTCTTGCCTTGTCCTCCG
CAGCATGTGATGCCTCCA
58 145
Caspase recruitment domain family, member 10 BG085048 Card10 TGAGCCTTCCTAGACCCTT
TGCCCATGAGAACTTGAGTG
58 275
Epoxide hydrolase 1, microsomal BG072453 Ephx1 CCAAGCCTGACACCGTAG
GCCAGTGGGCACATAGAC
58 278
UDP-N-acetyl-a-D-galactosamine/polypeptide BG068045 Galnt3 AGCGTTGGTCAGCCTCTA
GTTGTGCCGAATTTCATG
58 135
Kruppel-like factor 4 (gut) BG069413 Klf4 CCAGCCAGAAAGCACTAC
GACTCACCAAGCACCATC
55 409
Peptidylprolyl isomerase C BG065249 Ppic TCGGCTGCTGCTACCTCT
CTGCCAACATCTTTGTCTCC
55 144
Serine protease inhibitor, Kunitz type 2 BG085206 Spint2 CTTGGCTCAAAGGTGGTG
CAAATCCGAGTCAATCCC
55 263
Protein tyrosine phosphatase, receptor type F BG088014 Ptprf TCTGCTTCAAACCCTCAA
TCTGCTTCAAACCCTCAA
55 136
Transforming growth factor b2 BG067564 Tgfb2 ATTGCCCTCCTACAGACT
GTATCCATTTCCACCCTA
55 152
Tissue inhibitor of Metalloproteinase 1 NM_003254 TIMP1 ACAACCGCAGCGAGGAGT
AGGTGACGGGACTGGAAGC
55 262
Tissue inhibitor of Metalloproteinase 2 NM_003255 TIMP2 TTGACCCAGAGTGGAACG
ACCAAAGACGGGAGACGA
55 101
Tissue inhibitor of Metalloproteinase 3 NM_000362 TIMP3 GTTGTAGGGTTTCTGTTGT
GTGTTGTCTGCTGCTTTT
57 310
Tissue inhibitor of Metalloproteinase 4 NM_003256 TIMP4 TACCAGGCTCAGCATTAT
CCACTTGGCACTTCTTATT
55 232
Glyceraldehyde-3-phosphate dehydrogenase NM_002046 GAPDH AAGGATAATGGCTTACAAC
TCACTTAGGGCTTCTCAC
55 590Journal of Carcinogenesis 2007, 6:8 http://www.carcinogenesis.com/content/6/1/8
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CARD/MAGUK family member that signals the activation
of NF-κβ through BCL10. CARD10 and other members of
the CARD/MAGUK family likely play an important role in
receptor-mediated activation of BCL10 and NF-κβ [24].
Krüppel, a group of zinc-finger-containing transcription
factors found in Drosophila melanogaster, is thought to con-
trol embryogenesis [25]. Among these transcription fac-
tors, a group named Kruppel-like-factors (KLFs) has
recently emerged as important contributors to the devel-
opment of the mammalian embryo. The KLF family con-
sists of at least 16 members that have been separated into
subgroups based on their structure [26]. KFL4 was first
identified from a human umbilical vein erythroid cDNA
library. The Human KLF4 gene locus is located at chromo-
some 9q31, which covers a 6.3 kb region [27]. KLF4 has
been found to be important in regulating the proliferation
and differentiation of specific epithelial and endothelial
tissues [28]. The significant loss of KLF4 has been reported
in sporadic colonic adenomas and carcinomas [29], gas-
tric cancers [30], bladder cell lines and tissue [31], and
lung cancer [32]. The expression of KLF4 has been found
to be significantly repressed in human gliomas-associated
vascular endothelial cells as compared with that found in
non-neoplastic control vascular endothelial cells [33],
suggesting that KLF4 is involved in an anti-angiogenic
pathway.
Elevated expression of Serine protease inhibitor, Kunitz
type 2 (SPINT2)/Hepatocyte growth factor activator
inhibitor type 2 (HAI-2) (SPINT2/HAI-2) in both primary
and metastatic cell lines compared with the normal cell
lines with the highest expression levels occurring in the
metastatic cell lines. We additionally observed lowered
expression in AA cell lines compared to their CAU coun-
terparts. SPINT2/HAI-2 has a broad inhibitory spectrum
and was independently reported to be a placental bikunin
[34]. SPINT2/HAI-2 inhibits tissue and plasma kal-
likreins, trypsin, plasmin, factor XIa, and chymotrypsin.
Little is known about the in vivo functions of SPINT2/HAI-
2, but disruption of the HAI-2 gene has resulted in embry-
onic lethality in mice indicating a potentially important
role of this inhibitor in cellular development [35].
SPINT2/HAI-2 has been found to be over-expressed in
pancreatic cancer [36] and ovarian cancer [37] and has
been inversely correlated with tumor progression in renal
cell carcinoma [38] and breast cancer [39].
The data revealed elevated levels of ATP citrate lyase (Acly)
expression in both primary and metastatic cell lines com-
pared to the normal cell lines with the highest expression
levels occurring in the metastatic cell lines. We also
observed elevated expression found in AA cell lines com-
pared to their CAU counterparts. Acly is critical for the
conversion of glucose to cytosolic acetyl CoA and there-
fore for glucose-dependent lipogenesis. Acly deficiency in
mice has resulted in embryonic lethality, with no viable
embryos detectable even at early stages of development
[40]. Previous studies have noted that cancers exhibit high
levels of glycolysis and lipogenesis [41]. Accelerated fatty
acid synthesis (FAS) in tumor tissues was first reported in
the 1950s [42]. Elevated expression of FAS in malignant
Densitometric measurement of the 18S RT-PCR analyses Figure 1
Densitometric measurement of the 18S RT-PCR analyses. Using the data obtained from the RT-PCR experiments, the 
amplicons from three different experiments of each cell line was subjected to densitometric scanning. To determine the rela-
tive density, area plots were quantitated using the Chemi Imager Tm 4000 software (Alpha Innotect, Corp. San Leandro, CA). 
Values from the experiments were averaged and error bars represent the standard deviation.
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cells has been documented in various cancers including
breast [43-47], prostate [48-51], ovarian [52], endome-
trial [53], colon [54], tongue [55], lung carcinoma, [56]
and hepatocellular carcinoma [57].
In conclusion, we have amassed two cell line models that
could be used to identify biomarkers and treatments
unique to AA women with breast cancer. The significance
of the study is that Atp1b1, CARD 10, KLF4, Spint2, and
Acly are not only useful in serving as possible biomarkers
of metastasis, but also provide support for the concept
that they could serve specifically as biomarkers for AA
women. To date, this is the only study that has used an AA
model system specifically for gene mining to investigate
cancer and metastatic gene expression in cell lines derived
from African American patients.
Table 4: RT-PCR expression in AA and CAU cells. Expression assessment by RT-PCR of the targeted genes using the spectrum model. 
Altered expression in AA vs. CAU denoted in bold. Mean ± SD
African American Normal Caucasian
Cell Lines 2315 2329 2320 AG11132 MCF12A Hs578t 2336 MCF7
Gene Symbol
Card 10 46 ± 3.17 41 ± 3.49 32 ± 0.88 47 ± 3.05 51 ± 1.46 45 ± 0.71 45 ± 2.26 45 ± 0.24
Klf4 29 ± 0.72 30 ± 0.18 28 ± 0.75 45 ± 3.70 35 ± 1.62 30 ± 0.31 26 ± 4.69 31 ± 7.49
Acly 64 ± 0.66 61 ± 3.80 78 ± 0.01 60 ± 5.78 64 ± 8.04 52 ± 4.76 50 ± 6.17 64 ± 0.45
Atp1b1 60 ± 2.22 65 ± 4.69 57 ± 0.35 61 ± 3.00 57 ± 0.80 58 ± 0.26 51 ± 3.40 46 ± 1.48
Galnt3 37 ± 1.89 39 ± 0.40 43 ± 2.18 46 ± 0.74 56 ± 5.35 37 ± 1.37 27 ± 0.21 45 ± 1.06
Ppic 43 ± 0.76 42 ± 2.34 55 ± 0.56 46 ± 0.10 33 ± 1.60 44 ± 0.95 36 ± 2.01 43 ± 1.80
Ephx1 79 ± 4.67 67 ± 5.00 69 ± 6.29 65 ± 5.51 69 ± 6.20 73 ± 6.10 69 ± 1.18 71 ± 1.89
Spint2 60 ± 0.48 58 ± 2.24 42 ± 0.10 66 ± 6.79 69 ± 0.28 58 ± 0.58 60 ± 0.11 56 ± 1.39
Ptprf 32 ± 0.34 33 ± 0.15 35 ± 0.02 32 ± 0.33 27 ± 0.67 32 ± 0.01 58 ± 1.87 31 ± 0.08
Tgfb2 34 ± 0.55 37 ± 0.35 40 ± 3.22 35 ± 3.07 27 ± 0.58 42 ± 3.19 58 ± 5.44 32 ± 0.46
TIMP1 67 ± 2.10 64 ± 3.32 77 ± 3.48 57 ± 2.51 52 ± 6.11 47 ± 5.15 61 ± 2.22 74 ± 5.82
TIMP2 46 ± 4.79 66 ± 6.15 64 ± 6.95 57 ± 2.46 58 ± 8.11 48 ± 7.73 54 ± 1.16 64 ± 7.11
TIMP3 60 ± 0.08 65 ± 0.22 69 ± 0.76 56 ± 0.16 51 ± 0.22 52 ± 0.14 56 ± 0.37 76 ± 0.08
TIMP4 61 ± 0.39 63 ± 1.02 76 ± 3.38 63 ± 0.96 68 ± 7.29 77 ± 1.33 72 ± 0.16 75 ± 5.24
18S 90 ± 0.28 91 ± 0.60 89 ± 4.14 91 ± 1.75 89 ± 2.50 90 ± 1.80 89 ± 0.15 89 ± 4.98
GAPDH 83 ± 6.83 77 ± 2.34 76 ± 3.29 76 ± 0.91 75 ± 4.21 79 ± 1.55 80 ± 3.29 81 ± 7.70
Densitometric measurement of the GAPDH RT-PCR analyses Figure 2
Densitometric measurement of the GAPDH RT-PCR analyses. Using the data obtained from the RT-PCR experi-
ments, the amplicons from three different experiments of each cell line was subjected to densitometric scanning. To determine 
the relative density, area plots were quantitated using the Chemi Imager Tm 4000 software (Alpha Innotect, Corp. San Lean-
dro, CA). Values from the experiments were averaged and error bars represent the standard deviation.
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Table 5: RT-PCR expression of MMPs in AA and CAU cells. Expression assessment by RT-PCR of the targeted genes using the metastasis model. Altered expression in AA vs. CAU 
denoted in bold. Mean ± SD
African American Caucasian
Cell 
Lines
CRL 7721 HTB 24 CRL 2335 HTB 132 CRL 1504 CRL 2330 HTB 30 CRL 2327 CRL 2351 CAMA1 HTB 27 MCF7
Gene Symbol
Card 10 30 ± 1.08 38 ± 2.60 34 ± 2.55 35 ± 1.56 38 ± 2.60 33 ± 0.97 47 ± 0.02 55 ± 2.28 59 ± 2.72 58 ± 0.98 48 ± 1.43 45 ± 0.24
Klf4 34 ± 0.88 35 ± 1.60 38 ± 0.99 36 ± 1.83 34 ± 0.55 36 ± 0.06 44 ± 0.88 44 ± 0.38 45 ± 0.70 42 ± 0.47 44 ± 0.85 31 ± 1.49
Acly 80 ± 1.43 80 ± 2.08 86 ± 1.08 72 ± 0.006 68 ± 0.25 87 ± 0.64 64 ± 2.49 65 ± 2.11 69 ± 2.27 66 ± 2.11 60 ± 2.77 44 ± 0.45
Atp1b1 55 ± 0.39 56 ± 0.31 58 ± 1.02 57 ± 0.75 59 ± 0.02 55 ± 0.39 48 ± 1.07 47 ± 1.57 53 ± 1.41 48 ± 0.32 48 ± 2.51 46 ± 1.48
Galnt3 43 ± 2.30 42 ± 4.41 55 ± 0.41 60 ± 0.93 61 ± 1.57 49 ± 4.00 48 ± 0.65 57 ± 5.22 52 ± 1.47 53 ± 5.12 60 ± 1.49 45 ± 1.06
Ppic 49 ± 0.24 57 ± 1.02 59 ± 1.38 57 ± 0.45 61 ± 2.66 55 ± 2.46 57 ± 1.53 62 ± 1.01 62 ± 0.16 61 ± 2.71 59 ± 1.02 43 ± 1.80
Ephx1 48 ± 1.08 70 ± 0.06 63 ± 0.33 40 ± 0.52 38 ± 0.91 61 ± 1.08 53 ± 4.66 60 ± 1.16 66 ± 4.47 54 ± 0.88 72 ± 5.21 51 ± 1.89
Spint2 49 ± 2.77 43 ± 0.96 42 ± 0.70 54 ± 0.92 52 ± 0.11 44 ± 1.14 56 ± 1.24 55 ± 2.29 52 ± 2.76 53 ± 1.17 52 ± 0.76 56 ± 1.39
Ptprf 44 ± 1.27 40 ± 0.15 51 ± 3.00 45 ± 3.48 57 ± 3.25 52 ± 1.23 44 ± 1.90 48 ± 0.88 58 ± 0.87 55 ± 1.24 57 ± 2.89 31 ± 0.08
Tgfb2 34 ± 2.23 42 ± 0.55 39 ± 1.84 47 ± 4.51 43 ± 2.00 37 ± 1.16 33 ± 0.29 29 ± 1.95 39 ± 1.12 51 ± 4.43 34 ± 0.33 32 ± 0.46
TIMP1 68 ± 2.13 69 ± 0.31 63 ± 0.48 60 ± 1.30 67 ± 3.56 60 ± 1.30 84 ± 0.99 75 ± 4.73 59 ± 0.16 57 ± 1.18 56 ± 3.34 74 ± 5.82
TIMP2 59 ± 0.29 61 ± 3.43 62 ± 8.27 58 ± 0.44 64 ± 1.95 66 ± 4.45 64 ± 1.95 64 ± 0.77 61 ± 0.38 70 ± 5.21 53 ± 6.83 64 ± 7.11
TIMP3 83 ± 0.07 87 ± 0.09 62 ± 4.52 62 ± 3.93 84 ± 4.70 87 ± 0.75 57 ± 0.14 93 ± 1.14 77 ± 2.29 61 ± 1.17 83 ± 0.27 76 ± 0.08
TIMP4 70 ± 1.72 70 ± 5.23 69 ± 3.92 77 ± 1.65 79 ± 1.74 79 ± 1.07 64 ± 4.54 72 ± 0.43 66 ± 4.14 76 ± 2.18 73 ± 0.41 75 ± 5.24
18S 89 ± 0.98 90 ± 1.23 91 ± 1.19 89 ± 0.44 90 ± 2.22 90 ± 3.01 90 ± 0.67 89 ± 0.43 88 ± 1.51 88 ± 1.82 88 ± 1.73 89 ± 4.98
GAPDH 58 ± 1.34 57 ± 0.78 58 ± 2.12 56 ± 0.59 62 ± 0.28 48 ± 1.25 63 ± 0.71 49 ± 1.57 59 ± 1.19 56 ± 1.34 47 ± 0.41 81 ± 7.70Journal of Carcinogenesis 2007, 6:8 http://www.carcinogenesis.com/content/6/1/8
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Densitometric measurement of the SPINT2 RT-PCR analyses Figure 4
Densitometric measurement of the SPINT2 RT-PCR analyses. Using the data obtained from the RT-PCR experi-
ments, the amplicons from three different experiments of each cell line was subjected to densitometric scanning. To determine 
the relative density, area plots were quantitated using the Chemi Imager Tm 4000 software (Alpha Innotect, Corp. San Lean-
dro, CA). Values from the experiments were averaged and error bars represent the standard deviation.
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Densitometric measurement of the Atp1b1 RT-PCR analyses Figure 3
Densitometric measurement of the Atp1b1 RT-PCR analyses. Using the data obtained from the RT-PCR experi-
ments, the amplicons from three different experiments of each cell line was subjected to densitometric scanning. To determine 
the relative density, area plots were quantitated using the Chemi Imager Tm 4000 software (Alpha Innotect, Corp. San Lean-
dro, CA). Values from the experiments were averaged and error bars represent the standard deviation.
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Densitometric measurement of the CARD 10 RT-PCR analyses Figure 6
Densitometric measurement of the CARD 10 RT-PCR analyses. Using the data obtained from the RT-PCR experi-
ments, the amplicons from three different experiments of each cell line was subjected to densitometric scanning. To determine 
the relative density, area plots were quantitated using the Chemi Imager Tm 4000 software (Alpha Innotect, Corp. San Lean-
dro, CA). Values from the experiments were averaged and error bars represent the standard deviation.
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Densitometric measurement of the Acly RT-PCR analyses Figure 5
Densitometric measurement of the Acly RT-PCR analyses. Using the data obtained from the RT-PCR experiments, 
the amplicons from three different experiments of each cell line was subjected to densitometric scanning. To determine the 
relative density, area plots were quantitated using the Chemi Imager Tm 4000 software (Alpha Innotect, Corp. San Leandro, 
CA). Values from the experiments were averaged and error bars represent the standard deviation.
Acly Expression
0
20
40
60
80
100
African American     Caucasian
R
.
D
.
CRL 7721
HTB 24
CRL 2335
HTB 132
CRL 1504
CRL 2330
HTB 30
CRL 2327
CRL 2351
CAMA1
HTB 27
MCF7Journal of Carcinogenesis 2007, 6:8 http://www.carcinogenesis.com/content/6/1/8
Page 10 of 12
(page number not for citation purposes)
Densitometric measurements of the RT-PCR analyses Figure 8
Densitometric measurements of the RT-PCR analyses. Using the data obtained from the RT-PCR experiments, the 
amplicons from three different experiments of each cell line was subjected to densitometric scanning. To determine the rela-
tive density, area plots were quantitated using the Chemi Imager Tm 4000 software (Alpha Innotect, Corp. San Leandro, CA). 
Values from the experiments were averaged and error bars represent the standard deviation.
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Densitometric measurement of the Klf4 RT-PCR analyses Figure 7
Densitometric measurement of the Klf4 RT-PCR analyses. Using the data obtained from the RT-PCR experiments, the 
amplicons from three different experiments of each cell line was subjected to densitometric scanning. To determine the rela-
tive density, area plots were quantitated using the Chemi Imager Tm 4000 software (Alpha Innotect, Corp. San Leandro, CA). 
Values from the experiments were averaged and error bars represent the standard deviation.
Klf4 Expression
0
10
20
30
40
50
African American    Caucasian
R
.
D
.
CRL 7721
HTB 24
CRL 2335
HTB 132
CRL 1504
CRL 2330
HTB 30
CRL 2327
CRL 2351
CAMA1
HTB 27
MCF7Journal of Carcinogenesis 2007, 6:8 http://www.carcinogenesis.com/content/6/1/8
Page 11 of 12
(page number not for citation purposes)
Abbreviations
AA-African American women, CAU-Caucasian, RT-PCR-
Reverse transcriptase Polymerase Chain Reaction, ECM-
Extracellular matrix, MMP-Matrix Metalloproteinase
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
HFY conceived the study and participated in its design,
was responsible for primer design, performed data analy-
sis, densitometric readings of RT-PCR, and prepared the
first draft of the manuscript. JAM participated in the study
design, was responsible for primer design, performed the
RT-PCR experiments, was involved in tissue culture, and
prepared the first draft of the manuscript. SP performed
RT-PCR experiments, data analysis, densitometric read-
ings of the RT-PCR, and assisted in the editing of this man-
uscript. CETIII performed RT-PCR experiments, data
analysis and densitometric readings of the RT-PCR. GKL
participated in the funding, as well as data analysis and
editing of the manuscript. MJ participated in study con-
cept, design and data analysis. AAD participated in the
study concept, study design, secured funding, interpreta-
tion of the data, as well as preparation of the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
This work was supported by a grant from the US Army Research and 
Materiel Command under DAMD-17-01-1-0268 (Day and Jett) and DHHS/
NCI U54 CA091431 (Day). The views expressed by the authors in no way 
represent the United States Army. We would like to thank the Promega 
Corporation for their generous gifts of RT-PCR kits to aid in our research.
References
1. American Cancer Society: Cancer Facts & Figures 2006.  Atlanta:
American Cancer Society; 2006. 
2. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis
and angiogenesis: an imbalance of positive and negative reg-
ulation.  Cell 1991, 64(2):327-36.
3. American Cancer Society: Cancer Facts & Figures for African
Americans 2005–2006.  Atlanta: American Cancer Society; 2005. 
4. Ries L, Eisner M: SEER Cancer Statistics Review.  Bethesda,
National Cancer Institute:1975-2001. 
5. Bradley CJ, Given CW, Roberts C: Disparities in cancer diagnosis
and survival.  Cancer 2001, 91:178-188.
6. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB:
Survival of blacks and whites after a cancer diagnosis.  JAMA
2002, 287:2106-2113.
7. Ghafoor A, Jemal A, Cokkinides V, Cardinez C, Murray T, Samuels A,
Thun MJ: Cancer statistics for African Americans.  CA Cancer J
Clin 2002, 52:326-341.
8. Shavers V, Brown M: Racial and ethnic disparities in the receipt
of cancer treatment.  J Natl Cancer Inst 2002, 94:334-357.
9. Smedley B, Stith A: Unequal treatment: confronting racial and
ethnic disparities in health care. Committee on Understand-
ing and Eliminating Racial and Ethnic Disparities in Health
Care.  Washington, DC, National Academy Press; 2002. 
10. Chambers AF, Groom AC, MacDonald IC: Dissemination and
growth of cancer cells in metastatic sites.  Nat Rev Cancer 2002,
2:563-72.
11. Mason JA, Yancy HF, Lashley K, Jett M, Day AA: Comparative
study of matrix metalloproteinase expression between Afri-
can American and Caucasian Women.  Journal of Carcinogenesis
2004, 3:15.
12. Eckhardt B, Parker B, van Laar RK, Restall CM, Natoli AL, Tavaria
MD, Stanley KL, Sloan EK, Moseley JM, Anderson RL: Genomic
Analysis of a Spontaneous Model of Breast Cancer Metasta-
sis to Bone Reveals a Role for the Extracellular Matrix.  Mol
Cancer Res 2005, 3(1):1-13.
13. National Breast Cancer Foundation Inc: Based on information posted to
the NBCF web site 2005  [http://www.nationalbreastcancer.org/
signs_and_symptoms/index.html#breastcancertypes].
14. Haffty B, Silber A, Matloff E, Chung J, Lannin D: Racial Differences
in the incidence of BRCA1 and BRCA2 mutations in a cohort
of Early Onset Breast Cancer patients: African American
compared to White Women.  J Med Genet 2005:27.
15. .
16. Lingrel J, Orlowski J, Shull M, Price EM: Molecular genetics of Na,
K-ATPase.  Nucleic Acid Res Mol Biol 1990, 89:37-38.
17. Shull G, Greeb J, Lingrel J: Molecular cloning of three distinct
forms of the Na +, K +-ATPase β subunit from rat brain.  Bio-
chemistry 1986, 25:8125-8132.
18. Martin-Vasallo P, Dackowski W, Emanuel J, Levenson R: Identifica-
tion of a putative isoform of the Na, K-ATPase beta subunit.
J Biol Chem 1989, 264:4613-4318.
19. Good P, Richter K, Dawid IB: A nervous system-specific isotype
of the 13 subunit of Na +, K +-ATPase expressed during early
development of Xenopus laevis.  P r o c  N a t l  A c a d  S c i  1990,
87:9088-9092.
20. Young RM, Lingrel J: Tissue distribution of mRNAs encoding
the ~isoforms and 13 subunit of rat Na+, K+-ATPase.  Biochem
Biophys Res Commun 1987, 145:52-58.
21. Ouellet V, Provencher DM, Maugard CM, Le Page C, Ren F, Lussier
C, Novak J, Ge B, Hudson TJ, Tonin PN, Mes-Masson AM: Discrim-
ination between serous low malignant potential and invasive
epithelial ovarian tumors using molecular profiling.  Oncogene
2005, 24:4672-4687.
22. Hofmann K: The modular nature of apoptotic signaling pro-
teins.  Cell Mol Life Sci 1999, 55:1113-1128.
23. Bertin J, DiStefano PS: The PYRIN domain: a novel motif found
in apoptosis and inflammation proteins.  Cell Death Differ 2000,
7:1273-1274.
24. Staub E, Dahl E, Rosenthal A: The DAPIN family: a novel domain
links apoptotic and interferon response proteins.  Trends Bio-
chem Sci 2001, 26:83-85.
25. Wang L, Guo Y, Huang WJ, Ke X, Poyet JL, Manji GA, Merriam S,
Glucksmann A, DiStefano PS, Alnemri ES, Bertin J: Card10 is a novel
caspase recruitment domain/membrane-associated guan-
ylate kinase family member that interacts with BCL10 and
activates NF-kappa B.  J Biol Chem 2001, 276(24):21405-21409.
26. Schuh R, Aicher W, Gaul U, Cote S, Preiss A, Maier D, Seifert E, Nau-
ber U, Schroder C, Kemler R: A conserved family of nuclear pro-
teins containing structural elements of the finger protein
encoded by Krüppel, a Drosophila segmentation gene.  Cell
1986, 47:1025-1032.
27. Turner J, Crossley M: Mammalian Krüppel-like transcription
factors: more than just a pretty finger.  Trends Biochem Sci 1999,
24:236-240.
28. Yet SF, McA'Nulty MM, Folta SC, Yen HW, Yoshizumi M, Hsieh CM,
Layne MD, Chin MT, Wang H, Perrella MA, Jain MK, Lee ME: Krüp-
pel-like zinc finger protein is expressed in vascular endothe-
lial cells and contains transcriptional activation and
repression domains.  J Biol Chem 1998, 273:1026-1031.
29. Chen ZY, Shie J, Tseng C: Up-regulation of gut-enriched krüp-
pel-like factor by interferon-gamma in human colon carci-
noma cells.  FEBS Lett 2000, 477:67-72.
30. Shie JL, Chen ZY, O'Brien MJ, Pestell RG, Lee ME, Tseng CC: Role of
gut-enriched Krüppel-like factor in colonic cell growth and
differentiation.  Am J Physiol Gastrointest Liver Physiol 2000,
279:G806-G814.
31. Katz JP, Perreault N, Goldstein BG, Actman L, McNally SR, Silberg
DG, Furth EE, Kaestner KH: Loss of Klf4 in mice causes altered
proliferation and differentiation and precancerous changes
in the adult stomach.  Gastroenterology 2005, 128(4):935-45.
32. Ohnishi S, Ohnami S, Laub F, Aoki K, Suzuki K, Kanai Y, Haga K, Asaka
M, Ramirez F, Yoshida T: Downregulation and growth inhibitory
effect of epithelial-type Krüppel-like transcription factorPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Carcinogenesis 2007, 6:8 http://www.carcinogenesis.com/content/6/1/8
Page 12 of 12
(page number not for citation purposes)
KLF4, but not KLF5, in bladder cancer.  Biochem Biophys Res
Commun 2003, 308:251-256.
33. Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y,
Dufault MR, Zhang X, Zhang W, Walter-Yohrling J, Rouleau C,
Akmaev VR, Wang CJ, Cao X, St Martin TB, Roberts BL, Teicher BA,
Klinger KW, Stan RV, Lucey B, Carson-Walter EB, Laterra J, Walter
KA: Vascular gene expression in nonneoplastic and malig-
nant brain.  Am J Pathol 2004, 165:601-618.
34. Bianchi F, Hu J, Pelosi G, Cirincione R, Ferguson M, Ratcliffe C, Di
Fiore PP, Gatter K, Pezzella F, Pastorino U: Lung cancers detected
by screening with spiral computed tomography have a
malignant phenotype when analyzed by cDNA microarray.
Clin Cancer Res 2004, 15:6023-6028.
35. Delaria KA, Muller DK, Marlor CW, Brown JE, Das RC, Roczniak SO,
Tamburini PP: Characterization of placental bikunin, a novel
human serine protease inhibitor.  J Biol Chem 1997,
272:12209-1222.
36. Mitchell KJ, Pinson KI, Kelly OG, Brennan J, Zupicich J, Scherz P,
Leighton PA, Goodrich LV, Lu X, Avery BJ, Tate P, Dill K, Pangilinan
E, Wakenight P, Tessier-Lavigne M, Skarnes WC: Functional analy-
sis of secreted and transmembrane proteins critical to
mouse development.  Nat Genet 2001, 28:241-251.
37. Muller-Pillasch F, Wallrapp C, Bartels K, Varga G, Friess H, Buchler
M, Adler G, Gress TM: Cloning of a new Kunitz-type protease
inhibitor with a putative transmembrane domain overex-
pressed in pancreatic cancer.  Biochim Biophys Acta 1998,
1395:88-95.
38. Suzuki M, Kobayashi H, Tanaka Y, Hirashima Y, Kanayama N, Takei Y,
Saga Y, Suzuki M, Itoh H, Terao T: Suppression of invasion and
peritoneal carcinomatosis of ovarian cancer cell line by over-
expression of bikunin.  Int J Cancer 2003, 10: 104(3):289-302.
39. Yamauchi M, Kataoka H, Itoh H, Seguchi T, Hsaui Y, Osada Y: Hepa-
tocyte growth factor activator inhibitor type 1 and 2 are
expressed by tubular epithelium in kidney and downregu-
lated in renal cell carcinoma.  J Urol 2004, 171:890-896.
40. Parr C, Watkins G, Mansel RE, Jiang WG: The hepatocyte growth
factor regulatory factors in human breast cancer.  Clin Cancer
Res 2004, 10:202-211.
41. Beigneux AP, Kosinski C, Gavino B, Horton JD, Skarnes WC, Young
SG: ATP-citrate lyase deficiency in the mouse.  J Biol Chem
2004, 279:9557-9564.
42. Kuhajda FP: Fatty-acid synthase and human cancer: new per-
spectives on its role in tumor biology.  Nutrition 2000,
16(3):202-208.
43. Medes G, Thomas A, Weinhouse S: Metabolism of neoplastic tis-
sue. IV. A study of lipid synthesis in neoplastic tissue slices in
vitro.  Cancer Res 1953, 13:27-35.
44. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD,
Pasternack GR: Fatty acid synthesis: a potential selective tar-
get for antineoplastic therapy.  Proc Natl Acad Sci 1994,
91(14):6379-6383.
45. Alo' PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U: Expres-
sion of fatty acid synthase (FAS) as a predictor of recurrence
in stage I breast carcinoma patients.  Cancer 1996,
77(3):474-482.
46. Nakamura I, Kimijima I, Zhang GJ, Onogi H, Endo Y, Suzuki S, Tuchiya
A, Takenoshita S, Kusakabe T, Suzuki T: Fatty acid synthase
expression in Japanese breast carcinoma patients.  Int J Mol
Med 1999, 4(4):381-387.
47. Jensen V, Ladekarl M, Holm-Nielsen P, Melsen F, Soerensen FB: The
prognostic value of oncogenic antigen 519 (OA-519) expres-
sion and proliferative activity detected by antibody MIB-1 in
node-negative breast cancer.  J Pathol 1995, 176(4):343-352.
48. Jensen V, Ladekarl M, Holm-Nielsen P, Melsen F, Soerensen FB: Fatty
acid synthase (FAS) predictive strength in poorly differenti-
ated early breast carcinomas.  Tumori 1999, 85(1):35-40.
49. Epstein JI, Carmichael M, Partin AW: OA-519 (fatty acid synthase)
as an independent predictor of pathologic state in adenocar-
cinoma of the prostate.  Urology 1995, 45(1):81-86.
50. Shurbaji MS, Kalbfleisch JH, Thurmond TS: Immunohistochemical
detection of a fatty acid synthase (OA-519) as a predictor of
progression of prostate cancer.  Hum Pathol 1996,
27(9):917-921.
51. Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L,
Heyns W, Verhoeven G: Overexpression of fatty acid synthase
is an early and common event in the development of pros-
tate cancer.  Int J Cancer 2002, 98(1):19-22.
52. Gansler TS, Hardman W 3rd, Hunt DA, Schaffel S, Hennigar RA:
Increased expression of fatty acid synthase (OA-519) in ovar-
ian neoplasms predicts shorter survival.  Hum Pathol 1997,
28(6):686-692.
53. Pizer ES, Lax SF, Kuhajda FP, Pasternack GR, Kurman RJ: Fatty acid
synthase expression in endometrial carcinoma: correlation
with cell proliferation and hormone receptors.  Cancer 1998,
83(3):528-537.
54. Rashid A, Pizer ES, Moga M, Milgraum LZ, Zahurak M, Pasternack GR,
Kuhajda FP, Hamilton SR: Elevated expression of fatty acid syn-
thase and fatty acid synthetic activity in colorectal neoplasia.
Am J Pathol 1997, 150(1):201-208.
55. Krontiras H, Roye GD, Beenken SE, Myers RB, Mayo MS, Peters GE,
Grizzle WE: Fatty acid synthase expression is increased in
neoplastic lesions of the oral tongue.  Head Neck 1999,
21(4):325-329.
56. Piyathilake CJ, Frost AR, Manne U, Bell WC, Weiss H, Heimburger
DC, Grizzle WE: The expression of fatty acid synthase (FASE)
is an early event in the development and progression of squa-
mous cell carcinoma of the lung.  Hum Pathol 2000,
31(9):1068-1073.
57. Yahagi N, Shimano H, Hasegawa K, Ohashi K, Matsuzaka T, Najima Y,
Sekiya M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Nagai
R, Ishibashi S, Kadowaki T, Makuuchi M, Ohnishi S, Osuga J, Yamada
N: Co-ordinate activation of lipogenic enzymes in hepatocel-
lular carcinoma.  European Journal of Cancer 2005,
41(9):1316-1322.